Las Vegas—A significant shift remains underway in the U.S. pharmaceutical market, as specialty drugs, generics and biosimilars continue to take over where traditional medications once dominated.
Still, relatively slow uptake in the United States has meant lost opportunities for greater health care system savings and patient affordability, along with a mix of challenges and opportunities for providers, according to a pair of presentations at the 2017 14th Annual MHA Business